



Republic of the Philippines
Department of Health
OFFICE OF THE SECRETARY

MEDICINES RECOMMENDED FOR INCLUSION IN THE PHILIPPINE NATIONAL FORMULARY (PNF)

As of 07 September 2022, the Health Technology Assessment Council (HTAC) has completed the assessment and deliberation on zoledronic acid (4mg/5mL concentrated solution for IV infusion) for the treatment of patients with malignancy-related bone disease.

The HTAC hereby makes public its **preliminary recommendation for the government financing of zoledronic acid (4mg/5mL concentrated solution for IV infusion) through its inclusion in the Philippine National Formulary (PNF).**

Supporting studies that informed the recommendation of HTAC may be found in the evidence summary accessible through this link https://bit.ly/HTACPrelimRecom_ZoledronicAcid. All comments, inputs, and/or appeals may be submitted until **22 September 2022**, for the consideration of the HTAC, through email at hta@doh.gov.ph.

Please use the prescribed form for appeals which is accessible through this link hta.doh.gov.ph/topic-nomination/. Appeals not following the prescribed format, and those submitted beyond the deadline shall not be entertained.

Should you wish to submit hard copies, you may drop them off at the 4th floor, Philippine Blood Disease, and Transfusion Center, Lung Center Compound, Quezon Avenue, Quezon City.

ANNA MELISSA S. GUERRERO, MD, MPH (HTA)

Director IV

Health Technology Assessment Division

Health Regulation Team